US Drug Recall Register
Class I · High risk Terminated Initiated May 20, 2013 (13 years ago)

Methotrexate Injection

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter: Found during examination of retention samples.

What was recalled

Methotrexate Injection, USP, Preservative-Free, 1 g/40 mL (25 mg/mL), 40 mL Single Dose Vial, Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540; Manufactured by: EBEWE Pharma Ges.m.b.H. Nfg.KG, A-4866 Unterach, AUSTRIA, NDC 66758-041-01.

Recalling firm
Sandoz Incorporated
NDC code
66758-041-01
Origin
CO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-832-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Methotrexate recalls

See all
Class III · Low risk Completed

Methotrexate Tablets

Reason Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.

Amneal Pharmaceuticals, LLC NDC 69238-1423-1 D-0629-2024
Class III · Low risk Ongoing

Methotrexate Tablets

Reason Failed Tablet/Capsule Specifications: Tablets were observed to have an unsmooth surface with two tablets demonstrating illegible tablet identification and scoring.

West-Ward Columbus Inc D-0066-2024
Class II · Moderate risk Terminated

Methotrexate Intravitreal

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0221-2023
Class II · Moderate risk Terminated

Methotrexate

Reason Lack of Assurance of Sterility

Edge Pharma, LLC NDC 05446-1505-05 D-0406-2022
Class II · Moderate risk Terminated

Methotrexate Injection

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. NDC 61703-350-38 D-0553-2021